Connect (the free e-newsletter of National Seniors Australia) reported in June that USA regulators had approved a new drug for the treatment of Alzheimer’s disease. It was the first time since 2003 that a drug has been approved for the disease.
The drug, Aduhelm, has been shown to reduce levels of beta-amyloid, the sticky plaque that is the hallmark of Alzheimer’s disease in the brain.
It’s believed Aduhelm works most effectively the sooner the patient is diagnosed with Alzheimer’s, before damaging proteins, tau, can form.
In conjunction with the government approval, researchers are continuing to study Aduhelm and its effectiveness, as well as testing combination therapies involving the drug.
Aduhelm is under review by Australia’s Therapeutic Goods Administration (TGA), with a decision expected in early 2022. The full story can be found in the link.